Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Spranger

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
The Journal of Urology|June 7, 2002
Polyorchidism: a strange anomaly with unsuspected propertiesRobert Spranger, Marcel Gunst, Michael Kühn
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|September 23, 2015
[Safety monitoring of cell-based medicinal products (CBMPs)]Markus B Funk, Marion Frech, Robert Spranger, et al.
The Journal of Urology|November 21, 2002
Intravesical free-floating prostateRobert Spranger, Hannes Steiner, Andreas Berger, et al.
Diabetes, Obesity & Metabolism|April 16, 2020
Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trialYasuo Terauchi, Takahiro Nakama, Robert Spranger, et al.
Diabetes Care|April 17, 2020
Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical TrialHirotaka Watada, Akane Takami, Robert Spranger, et al.
Diabetes, Obesity & Metabolism|February 20, 2020
Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trialHideaki Kaneto, Akane Takami, Robert Spranger, et al.
European Journal of Endocrinology|September 1, 2005
Hypoxia-induced leptin production in human trophoblasts does not protect from apoptosisUdo Meissner, Robert Spranger, Manfed Lehner, et al.
The Journal of Urology|August 13, 2003
Congenital absence of the right renal veinGermar-M Pinggera, Robert Spranger, Ferdinand Frauscher, et al.
The Prostate|September 2, 2003
Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimensAndreas P Berger, Robert Spranger, Kurt Kofler, et al.
European Urology|February 5, 2003
Transurethral microwave thermotherapy (TUMT) with the Targis System: a single-centre study on 78 patients with acute urinary retention and poor general healthAndreas P Berger, Mathias Niescher, Robert Spranger, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
The Journal of Urology|June 7, 2002
Polyorchidism: a strange anomaly with unsuspected propertiesRobert Spranger, Marcel Gunst, Michael Kühn
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|September 23, 2015
[Safety monitoring of cell-based medicinal products (CBMPs)]Markus B Funk, Marion Frech, Robert Spranger, et al.
The Journal of Urology|November 21, 2002
Intravesical free-floating prostateRobert Spranger, Hannes Steiner, Andreas Berger, et al.
Diabetes, Obesity & Metabolism|April 16, 2020
Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trialYasuo Terauchi, Takahiro Nakama, Robert Spranger, et al.
Diabetes Care|April 17, 2020
Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical TrialHirotaka Watada, Akane Takami, Robert Spranger, et al.
Diabetes, Obesity & Metabolism|February 20, 2020
Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trialHideaki Kaneto, Akane Takami, Robert Spranger, et al.
European Journal of Endocrinology|September 1, 2005
Hypoxia-induced leptin production in human trophoblasts does not protect from apoptosisUdo Meissner, Robert Spranger, Manfed Lehner, et al.
The Journal of Urology|August 13, 2003
Congenital absence of the right renal veinGermar-M Pinggera, Robert Spranger, Ferdinand Frauscher, et al.
The Prostate|September 2, 2003
Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimensAndreas P Berger, Robert Spranger, Kurt Kofler, et al.
European Urology|February 5, 2003
Transurethral microwave thermotherapy (TUMT) with the Targis System: a single-centre study on 78 patients with acute urinary retention and poor general healthAndreas P Berger, Mathias Niescher, Robert Spranger, et al.
Pageof 2